Duvelisib was the next PI3K inhibitor authorised with the FDA, also dependant on a section III randomized trial.130 The efficacy and protection profile from the drug seem equivalent with those of idelalisib, if not a little bit beneficial. Relating to alternative BTK inhibitors, there are many products and solutions in enhancement, but only acalabr